Tekla Capital Management LLC Jounce Therapeutics, Inc. Transaction History

Tekla Capital Management LLC

  • $2.53 Billion
  • Q2 2023

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$5.04 - $8.73 $1.93 Million - $3.34 Million
-382,237 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$6.73 - $13.87 $2.57 Million - $5.3 Million
382,237 New
382,237 $3.93 Million
Q2 2019

Aug 14, 2019
SELL
$4.3 - $6.73 $43,546 - $68,154
-10,127 Closed
0 $0
Q1 2018

May 14, 2018
BUY
$13.4 - $28.4 $135,701 - $287,606
10,127 New
10,127 $226,000

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email